Published in Biomed Res Int on March 29, 2015
Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Retracted: The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. Biomed Res Int (2016) 0.75
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Hepatocellular carcinoma. Lancet (2003) 22.54
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 19.03
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 3.99
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol (2001) 2.99
Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol (2012) 2.89
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology (2005) 2.04
Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. J Cell Biol (2008) 1.92
Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett (2007) 1.91
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer (2011) 1.73
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol (2006) 1.69
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64
The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res (2009) 1.64
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol (2004) 1.56
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res (2010) 1.47
A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med (2008) 1.46
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol (2009) 1.44
Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am (2014) 1.44
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res (2004) 1.42
Hepatocellualar carcinoma serum markers. Semin Oncol (2012) 1.39
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother (2010) 1.38
Percutaneous ethanol injection therapy for hepatocellular carcinoma. A histopathologic study. Cancer (1991) 1.38
What is changing in indications and treatment of hepatic hemangiomas. A review. Ann Hepatol (2014) 1.37
Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology (1998) 1.36
Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol (2008) 1.30
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun (2014) 1.24
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology (2011) 1.24
Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology (2013) 1.23
Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg (2008) 1.20
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Regulation of tumour immunity by CD25+ T cells. Immunology (2002) 1.16
Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology (2006) 1.16
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology (2008) 1.12
Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol (2010) 1.11
Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res (2006) 1.09
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
Serum markers of intrahepatic cholangiocarcinoma. Dis Markers (2013) 1.07
Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology (1996) 1.07
Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med (2011) 1.04
Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother (2013) 1.03
Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol (2013) 1.03
Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract (2012) 1.00
Immunotherapy of HCC. Rev Recent Clin Trials (2008) 1.00
Immunotherapy of hepatocellular carcinoma. J Hepatol (2006) 1.00
Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res (2014) 0.99
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 0.99
The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res (2004) 0.98
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol (2011) 0.98
Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol (2013) 0.98
Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl (2014) 0.97
Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol (2005) 0.97
Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology (1997) 0.97
Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology (2013) 0.96
Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin Biol Ther (2010) 0.94
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol (2014) 0.93
Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer (2013) 0.93
A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res (2010) 0.93
Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect (2010) 0.92
NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett (2011) 0.89
Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg (2012) 0.89
EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma. Clin Cancer Res (2014) 0.88
Rare benign tumors of the liver: still rare? J Gastrointest Cancer (2014) 0.88
Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation. Oncotarget (2014) 0.88
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res (2011) 0.88
Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology (2014) 0.87
Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol (2004) 0.87
Telomere and telomerase in chronic liver disease and hepatocarcinoma. World J Gastroenterol (2014) 0.85
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis (2012) 0.84
Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. World J Surg Oncol (2012) 0.84
Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example. Biochem Biophys Res Commun (2005) 0.84
Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One (2011) 0.84
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets (2014) 0.84
Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology (2011) 0.83
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol (2012) 0.83